 LEXINGTON, Mass. , Jan. 23, 2023 PRNewswire -- Pulmatrix, Inc. NASDAQ: PULM, a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSETM technology, today announced the acceptance of an abstract for presentation at the American Academy of Allergy, Asthma and Immunology AAAI Annual Meeting, to be held February 24-27, 2023 in San Antonio, Texas. 